北京商报讯(记者丁宁)5月20日,三生制药(01530.HK)盘中股价大涨,截至北京商报记者发稿,报19.68港元/股,涨幅为35.72%。 消息面上,三生制药及其子公司将PD-1/VEGF双特异性抗体SSGJ-707的全球(除中国内地)开发、生产和商业化权益独家授权给辉瑞。三生制药将获得12.5亿美元的首付款。里程碑付款最高可达48亿美元,涵盖开发、监管和销售里程碑。三生制药将获得许可地区产品...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.